# Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

> **NCT00543543** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 14840 (actual)

## Conditions studied

- Cervical Cancer
- Vulvar Cancer
- Vaginal Cancer
- Genital Warts
- Human Papillomavirus Infection

## Interventions

- **BIOLOGICAL:** Comparator: GARDASIL
- **BIOLOGICAL:** Experimental: V503

## Key facts

- **NCT ID:** NCT00543543
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-24
- **Primary completion:** 2013-04-10
- **Final completion:** 2016-07-07
- **Target enrollment:** 14840 (ACTUAL)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543543, "Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00543543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*